WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
SINGAPORE, June 5, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its...
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in...